Bextra (valdecoxib)
- Region
- 🇪🇺 EU
- Active substance
- valdecoxib
- Company
- Pharmacia - Pfizer EEIG
- Status
- Withdrawn
- Therapeutic area
- Arthritis, Rheumatoid; Osteoarthritis; Dysmenorrhea
- EU approval
- Thu 27 Mar 2003
- Application
- EMEA/H/C/000431
- ATC
- M01AH03
- Official record
- www.ema.europa.eu
Indication
Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea. The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risk (see sections 4.3, 4.4).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Valdyn Withdrawn · Pharmacia Europe EEIG
- 🇪🇺 Valdyn (previously Kudeq) Withdrawn · Pfizer Limited
Follow Bextra
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.